Vincristine neurotoxicity.
D000005:Abdomen; D001341:Autonomic Nervous System; D001369:Axons / Q000187:drug effects; D003248:Constipation / Q000139:chemically induced; D003391:Cranial Nerves; D003863:Depression / Q000139:chemically induced; D003929:Diabetic Neuropathies / Q000150:complications; D004347:Drug Interactions; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D007415:Intestinal Obstruction / Q000139:chemically induced; D009133:Muscular Atrophy / Q000150:complications; D009422:Nervous System Diseases / Q000139:chemically induced*; D009431:Neural Conduction / Q000187:drug effects; D009638:Norepinephrine / Q000097:blood; D010146:Pain / Q000139:chemically induced; D010292:Paresthesia / Q000139:chemically induced; D010300:Parkinson Disease / Q000150:complications; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D012640:Seizures / Q000139:chemically induced; D014667:Vasopressins / Q000378:metabolism; D014750:Vincristine / Q000494:pharmacology / Q000633:toxicity*
D014667:Vasopressins; D014750:Vincristine; D009638:Norepinephrine